Halozyme, Inc.

We are wrapping up our time at Controlled Release Society's Annual Meeting and Expo with a presentation titled “Clinical Trial to investigate the Tolerability of a Rapid 10 mL Subcutaneous Injection of a Biologic Drug with Recombinant Human Hyaluronidase (rHuPH20) Using a High Volume Auto-injector (HVAI) in Healthy Subjects”. Join David Kang tomorrow, Friday, July 12 from 8 am in the Emilia room. https://ow.ly/oUqM50Sz7cF #Halozyme #subcutaneous

At Controlled Release Society's Annual Meeting and Expo this week? Come check out David Kang and Manuel Sanchez-Felix's poster “Preclinical Evaluation of a High-Volume Auto-injector (HVAI) for Subcutaneous Injection of a Biologic Drug with Recombinant Human Hyaluronidase PH20 (rHuPH20)." Come swing by and say hello! #Halozyme #subcutaneous

Just a reminder: if you are attending Controlled Release Society's Annual Meeting and Expo this week, be sure to check out David Kang presentation tomorrow from 9:55-10:15 on “High Volume Subcutaneous Injection Device: Pushing the Injection Volume Boundaries.” https://ow.ly/gj9F50Su0Up #Halozyme #subcutaneous

Attending Controlled Release Society's Annual Meeting and Expo next week? Drop us a line to set up a meeting with David Kang Marie Printz or Manuel Sanchez-Felix and learn more about how Halozyme is reinventing the patient experience. We are also participating in the following events during the conference – we would love to see you! • Oral Presentation – David Kang – “High Volume Subcutaneous Injection Device: Pushing the Injection Volume Boundaries” on Monday, July 8 from 9:55-10:15 • Workshop – presented together with members of the Subcutaneous Drug Delivery and Development Consortium – “Debunking the Myths of Subcutaneous Drug Delivery” on Monday, July 8 from 13:00-16:00 • Oral Presentation – David Kang – “Clinical Trial to investigate the Tolerability of a Rapid 10 mL Subcutaneous Injection of a Biologic Drug with Recombinant Human Hyaluronidase (rHuPH20) Using a High Volume Auto-injector (HVAI) in Healthy Subjects” on Friday, July 12 from 8:00-10:00 • Poster presentation – developed by Manuel Sanchez-Felix and David Kang – “Preclinical Evaluation of a High-Volume Auto-injector (HVAI) for Subcutaneous Injection of a Biologic Drug with Recombinant Human Hyaluronidase PH20 (rHuPH20)” – available for viewing throughout the Congress #Halozyme #SCConsortium #subcutaneous

Happy Fourth of July from the Halozyme team! Have a wonderful and safe holiday! #FourthofJuly #IndependanceDay #Freedom

#ICYMI, members of the Subcutaneous Drug Development & Delivery Consortium – including Halozyme’s Manuel Sanchez-Felix – recently published a paper on “Optimizing Patient Experience and Treatment Adherence through SC Product Design.” The paper can be viewed here: https://ow.ly/Bv8v50Su05B #Halozyme #SCConsortium #subcutaneous

Attending the Controlled Release Society's Annual Meeting and Exposition next week in Bologna? Join Halozyme, Roche and other members of the Subcutaneous Drug Development & Delivery Consortium for a workshop on “Debunking the Myths of Subcutaneous Drug Delivery” on Monday, July 8 from 1:00 p.m. – 5:00 p.m. https://ow.ly/Je0o50StZOc #Halozyme #SCConsortium #subcutaneous

Our partner argenx announced FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The treatment is co-formulated with Halozyme's drug delivery technology. We are so proud of the work we are doing with our partners to create improved treatment options that provide meaningful benefits for patients and healthcare providers. https://ow.ly/tTK050SoxMB #Halozyme #subcutaneous #CIDP

Based on the new European patent for ENHANZE®, Halozyme recently raised our full year 2024 financial guidance and updated our 5-year financial outlook. "We are pleased to be able to raise our full year 2024 financial guidance and 5-year financial outlook, which now reflect the original royalty rate for DARZALEX SC in Europe from the granting of this new European patent, which is valid through March 6, 2029," said Dr. Helen Torley, president and chief executive officer of Halozyme. For the full year 2024, the Company expects: • Total revenue of $935 million to $1,015 million, representing growth of 13% to 22% over 2023, primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED®. • Revenue from royalties of $520 million to $555 million, representing growth of 16% to 24% over 2023. • Adjusted EBITDA of $555 million to $615 million, representing growth of 30% to 44% over 2023. • Non-GAAP diluted earnings per share of $3.65 to $4.05, representing growth of 32% to 46% over 2023. The Company's earnings per share guidance does not consider the impact of potential future share repurchases. The full press release can be found here: https://ow.ly/7y1U50SbflM Halozyme also provided additional details on the new European patent and our 5-year financial outlook on a conference call; a recording is available here: https://ow.ly/5Yjp50SbflL

Yesterday, Halozyme announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. Halozyme discussed the new European patent and provided an update to its 2024 financial guidance and 5-year financial outlook on a conference call earlier today. To access the webcast and presentation, please visit https://ow.ly/QIQ050Sb7Qt. The press release announcing the patent can be found here: https://ow.ly/s2lW50Sb7Qs